Familial Pulmonary Fibrosis research hub
4 indexed studies · 3 currently recruiting
- recruitingPHASE3
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
This study investigates if a new drug, nerandomilast, can slow down lung changes in people aged 40+ with a family history of lung scarring (pulmonary fibrosis) and early changes seen on a lung scan. Participants receive either the drug or a dummy pill.
United States · Argentina · Australia - recruitingPHASE3
A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases
This study looks at a new medicine, nerandomilast, for people with lung scarring (fibrosis) linked to rheumatic diseases. It aims to see if nerandomilast improves lung function when standard treatments haven't helped. Participants take tablets for several months, with regular check-ups.
United States · Australia · Austria - active not recruiting
Clinical Course of Interstitial Lung Diseases: European IPF Registry and Biobank
This study collects information and samples from people with rare lung conditions, including Idiopathic Pulmonary Fibrosis (IPF). It aims to understand these diseases better and help find new treatments. It's a Europe-wide effort to improve care for patients.
Austria · France · Germany - not yet recruitingPHASE3
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
This study tests a new medicine called nerandomilast for people with certain types of lung scarring (fibrosing interstitial lung disease). It aims to see if the medicine can stop the disease from getting worse. Participants take the medicine or a dummy pill, and doctors check their lung health over about two years.
United States · Argentina · Austria